European application, no grantEurope
Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
EP 1017829 A2 · Applicant: ARIAD GENE THERAPEUTICS, INC.
Overview
The published document from the EPO: abstract, claims, description and drawings. Open it full size
Read the whole patent
Listed from its EPO record in Patent Yard's archive of European patents past their term. Its claims, description and drawings are in the EPO PDF and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 26, 1998 and never granted as a European patent. Had it been granted, its 20-year term would have ended August 26, 2018.
- A supplementary protection certificate, which can extend a medicine or crop-protection patent, adds at most five and a half years, so even that would have ended by February 26, 2024.
- We check European rights only. A US or other national patent in its family could still be in force: check its family on Espacenet or Google Patents.
FiledAugust 26, 1998
PublishedJuly 12, 2000
GrantedNever granted
Term endedAugust 26, 2018
Application numberEP 98942265
Classification (CPC)C07K14/005 +2 more
Timeline
Timeline From EPO dates
Sources & verification
Official EPO records
Everything on this page comes from the EPO record linked above. EPO data used under CC BY 4.0.